the staff of the Ridgewood blog
Ridgewood NJ, in a significant development, outside advisers to the U.S. Food and Drug Administration (FDA) unanimously endorsed the efficacy of Eli Lilly’s experimental Alzheimer’s drug, donanemab, for patients with early Alzheimer’s disease. This vote precedes the FDA’s impending decision on the drug’s approval. The panel’s discussion highlighted some unique aspects of Lilly’s trial, which differed notably from the trial design of Eisai and Biogen’s Leqembi, another Alzheimer’s drug that recently gained U.S. approval following a similar advisory committee review.
Continue reading FDA Panel Endorses Eli Lilly’s Experimental Alzheimer’s Drug Donanemab
